Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease
New England Journal of Medicine · 2024
DOI: 10.1056/nejme2405647 ↗Kurz gefasst
Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Pradeep Natarajan. Beteiligte Einrichtung: From the Department of Medicine and Division of Cardiology, Massachusetts General Hospital and Harvard Medical School - both in Boston. Hauptthemen laut MEDLINE: Coronary Artery Disease, PCSK9 Inhibitors, RNA, Small Interfering, RNAi Therapeutics. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
The increasingly widespread availability of genomic sequencing has enabled the identification of persons and families with uniquely favorable traits, including a very low incidence of clinical events. Such exceptional persons across diverse communities are playing an important role in the genesis of medicines for common cardiovascular diseases. The discovery of proprotein convertase subtilisin–kexin type 9 (PCSK9) as a therapeutic target for coronary artery disease established a playbook. Approximately 20 years ago, positional cloning of a novel candidate locus of families with familial hypercholesterolemia living in France and Utah identified gain-of-function variants in PCSK9 . In short course, targeted sequencing of PCSK9 . . .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Medicine and Division of Cardiology, Massachusetts General Hospital and Harvard Medical School - both in Boston.
ORCID-Profile: Pradeep Natarajan
Zitieren
APA
Natarajan, P. (2024). Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease. New England Journal of Medicine. https://doi.org/10.1056/nejme2405647
Vancouver
Natarajan P. Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease. New England Journal of Medicine. 2024. doi:10.1056/nejme2405647
BibTeX
@article{Natarajan2024,
author = {Natarajan, Pradeep},
title = {Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejme2405647}
}
EUVIMED